Spruce Biosciences, Inc.
Corticotropin releasing factor receptor antagonists
Last updated:
Abstract:
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethyl- pyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Status:
Grant
Type:
Utility
Filling date:
22 Oct 2020
Issue date:
18 May 2021